Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 15/20 | 0.56 |
| ▸ | UBA3 | Q8TBC4 | 15/20 | 0.56 |
| ▸ | UBA1 | P22314 | 1/20 | 0.45 |
| ▸ | UBE2E1 | P51965 | 1/20 | 0.45 |
| ▸ | ATG7 | O95352 | 2/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL783622 | 0.86 | NAE1 (0.60) | NAE1UBA3UBA1UBE2E1 | |
| SCHEMBL782316 | 0.83 | NAE1 (0.80) | NAE1UBA3UBA1UBE2E1PI4KA | |
| SCHEMBL782553 | 0.78 | NAE1 (0.67) | NAE1UBA3 | |
| SCHEMBL16870075 | 0.76 | NAE1 (0.58) | NAE1UBA3UBA1UBE2E1 | |
| SCHEMBL12392774 | 0.76 | NAE1 (0.58) | NAE1UBA3UBA1UBE2E1 | |
| SCHEMBL783824 | 0.76 | NAE1 (0.58) | NAE1UBA3UBA1UBE2E1 | |
| SCHEMBL782739 | 0.76 | NAE1 (0.53) | NAE1UBA3UBA1UBE2E1 | |
| SCHEMBL15007431 | 0.75 | NAE1 (0.45) | NAE1UBA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL783023 | 0.73 | NAE1 (0.58) | NAE1UBA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL14720050 | 0.73 | NAE1 (0.45) | NAE1UBA3PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | NAE1 24/4885UBA3 6/4885UBA1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.